Cargando…
Study protocol of the HD-MED study aiming to personalize drug treatment in Huntington’s disease: a longitudinal, observational study to assess medication use and efficacy in relation to pharmacogenetics
BACKGROUND: Huntington’s disease (HD) is a hereditary, neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. Currently, HD can only be managed symptomatically, including a large variety of prescribed drugs. Many HD patients experience negative medication effects (e....
Autores principales: | Feleus, Stephanie, van der Lee, Maaike, Swen, Jesse J., Roos, Raymund A. C., de Bot, Susanne T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634258/ https://www.ncbi.nlm.nih.gov/pubmed/37955016 http://dx.doi.org/10.1177/26330040231204643 |
Ejemplares similares
-
The Many Faces of Huntington’s Chorea Treatment: The Impact of Sudden Withdrawal of Tiapride after 40 Years of Use and a Systematic Review
por: Feleus, Stephanie, et al.
Publicado: (2022) -
Machine learning in Huntington’s disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction
por: Ouwerkerk, Jasper, et al.
Publicado: (2023) -
Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
por: Klöppel, Stefan, et al.
Publicado: (2015) -
Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington’s disease
por: van de Zande, Nadine Anniek, et al.
Publicado: (2023) -
More than a co-incidence? Comment on: Amyotrophic lateral sclerosis is over‐represented in two Huntington’s disease brain bank cohorts: further evidence to support genetic pleiotropy of pathogenic HTT gene expansion
por: Bakels, Hannah S., et al.
Publicado: (2022)